A randomized crossover trial tested the short-term efficacy and safety of topical timolol maleate ophthalmic solution 0.5% in acute migraine. The trial involved 60 participants who experienced migraines with aura who were randomly assigned to receive either timolol or placebo eye drops. The primary outcome was reduction in headache severity 2 hours after treatment, with secondary outcomes including adverse effects. Results showed timolol provided greater reduction in headache severity than placebo with no serious adverse effects reported.